{"disease":{"id":"acute-mi","name":"acute mi"},"drugs":{"marketed":[{"drug_id":"venetoclax","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venclexta","generic_name":"venetoclax","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Apoptosis regulator Bcl-2","drug_class":"BCL-2 Inhibitor [EPC]","quality_score":80,"revenue":"2583","mechanism":"Venclexta is a selective and orally bioavailable small-molecule inhibitor of BCL-2, an anti-apoptotic protein."},{"drug_id":"nivestym","indication_name":"Refractory acute myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neupogen","generic_name":"Filgrastim-Aafi","company_name":"Amgen","drug_phase":"marketed","molecular_target":"G-CSF receptor (granulocyte colony-stimulating factor receptor)","drug_class":"Colony-stimulating factor (CSF); leukocyte growth factor","quality_score":10,"revenue":"1434.0","mechanism":"Filgrastim-aafi binds G-CSF receptors on hematopoietic cells, stimulating neutrophil proliferation, differentiation, and functional activation."},{"drug_id":"nivestym","indication_name":"Relapsed acute myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neupogen","generic_name":"Filgrastim-Aafi","company_name":"Amgen","drug_phase":"marketed","molecular_target":"G-CSF receptor (granulocyte colony-stimulating factor receptor)","drug_class":"Colony-stimulating factor (CSF); leukocyte growth factor","quality_score":10,"revenue":"1434.0","mechanism":"Filgrastim-aafi binds G-CSF receptors on hematopoietic cells, stimulating neutrophil proliferation, differentiation, and functional activation."},{"drug_id":"blinatumomab","indication_name":"Pre B-cell acute lymphoblastic leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Blincyto","generic_name":"blinatumomab","company_name":"Amgen","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD19","drug_class":"Bispecific CD19-directed CD3-directed T Cell Engager","quality_score":73,"revenue":"1000","mechanism":"Blincyto works by binding to both T cells and cancer cells, directing the T cells to kill the cancer cells."},{"drug_id":"cyclophosphamide","indication_name":"Acute lymphoid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytoxan (Lyophilized)","generic_name":"cyclophosphamide","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Tumor cell DNA","drug_class":"Alkylating agent","quality_score":10,"revenue":"1000.0","mechanism":"Cyclophosphamide cross-links tumor cell DNA and interferes with malignant cell growth through active alkylating metabolites."},{"drug_id":"cyclophosphamide","indication_name":"Acute monocytic leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytoxan (Lyophilized)","generic_name":"cyclophosphamide","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Tumor cell DNA","drug_class":"Alkylating agent","quality_score":10,"revenue":"1000.0","mechanism":"Cyclophosphamide cross-links tumor cell DNA and interferes with malignant cell growth through active alkylating metabolites."},{"drug_id":"cyclophosphamide","indication_name":"Acute myelogenous leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytoxan (Lyophilized)","generic_name":"cyclophosphamide","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Tumor cell DNA","drug_class":"Alkylating agent","quality_score":10,"revenue":"1000.0","mechanism":"Cyclophosphamide cross-links tumor cell DNA and interferes with malignant cell growth through active alkylating metabolites."},{"drug_id":"rimegepant-75mg-every-other-day-dosing","indication_name":"Acute treatment of migraine attacks with or without aura in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimegepant 75mg every other day dosing","generic_name":"rimegepant-75mg-every-other-day-dosing","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"calcitonin gene-related peptide receptor","drug_class":"calcitonin gene-related peptide receptor antagonist","quality_score":64,"revenue":"798","mechanism":"Rimegepant targets the calcitonin gene-related peptide receptor to treat migraines."},{"drug_id":"asparaginase","indication_name":"Acute Lymphoblastic Leukemia (ALL)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Elspar","generic_name":"ASPARAGINASE","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"L-asparagine","drug_class":"Asparagine-specific Enzyme [EPC]","quality_score":10,"revenue":"600","mechanism":"RYLAZE kills leukemic cells by depleting plasma asparagine, which they need for survival."},{"drug_id":"gilteritinib","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xospata","generic_name":"GILTERITINIB","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"Leukocyte tyrosine kinase receptor","drug_class":"","quality_score":65,"revenue":"600","mechanism":"Xospata works by blocking the activity of a specific enzyme called Leukocyte tyrosine kinase receptor."},{"drug_id":"asparaginase","indication_name":"Acute lymphoid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Elspar","generic_name":"ASPARAGINASE","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"L-asparagine","drug_class":"Asparagine-specific Enzyme [EPC]","quality_score":10,"revenue":"600","mechanism":"RYLAZE kills leukemic cells by depleting plasma asparagine, which they need for survival."},{"drug_id":"dasatinib","indication_name":"Philadelphia chromosome-positive acute lymphoblastic leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sprycel","generic_name":"dasatinib","company_name":"Handa Therap","drug_phase":"marketed","molecular_target":"Ephrin type-B receptor 6","drug_class":"dasatinib","quality_score":74,"revenue":"493","mechanism":"Sprycel works by blocking the activity of a specific protein called Ephrin type-B receptor 6, which is involved in the growth and survival of cancer cells."},{"drug_id":"besponsa","indication_name":"Relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Besponsa","generic_name":"Inotuzumab Ozogamicin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"CD22","drug_class":"Antibody-drug conjugate (ADC)","quality_score":10,"revenue":"200","mechanism":"CD22-directed antibody-drug conjugate delivering cytotoxic calicheamicin to induce DNA breaks and apoptosis."},{"drug_id":"inotuzumab","indication_name":"Relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Besponsa","generic_name":"inotuzumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD22","drug_class":"CD22-directed Immunoconjugate [EPC]","quality_score":68,"revenue":"200","mechanism":"Inotuzumab ozogamicin is a CD22-directed antibody drug conjugate that targets and kills cancer cells."},{"drug_id":"inotuzumab","indication_name":"Relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in pediatric patients 1 year and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Besponsa","generic_name":"inotuzumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD22","drug_class":"CD22-directed Immunoconjugate [EPC]","quality_score":68,"revenue":"200","mechanism":"Inotuzumab ozogamicin is a CD22-directed antibody drug conjugate that targets and kills cancer cells."},{"drug_id":"besponsa","indication_name":"Relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in pediatric patients 1 year and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Besponsa","generic_name":"Inotuzumab Ozogamicin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"CD22","drug_class":"Antibody-drug conjugate (ADC)","quality_score":10,"revenue":"200","mechanism":"CD22-directed antibody-drug conjugate delivering cytotoxic calicheamicin to induce DNA breaks and apoptosis."},{"drug_id":"midostaurin","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rydapt","generic_name":"MIDOSTAURIN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Mast/stem cell growth factor receptor Kit","drug_class":"Kinase Inhibitor [EPC]","quality_score":62,"revenue":"200","mechanism":"Rydapt blocks the activity of the Kit receptor, which is involved in the growth and survival of cancer cells."},{"drug_id":"inotuzumab-ozogamicin","indication_name":"Pre B-cell acute lymphoblastic leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Besponsa","generic_name":"inotuzumab-ozogamicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD22","drug_class":"Antibody-drug conjugate (ADC)","quality_score":78,"revenue":"200","mechanism":"CD22-directed antibody-drug conjugate delivering cytotoxic calicheamicin to induce DNA breaks and apoptosis."},{"drug_id":"glasdegib","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Daurismo","generic_name":"glasdegib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Smoothened homolog","drug_class":"Hedgehog Pathway Inhibitor [EPC]","quality_score":10,"revenue":"150","mechanism":"Daurismo works by blocking the Smoothened homolog, a protein involved in the Hedgehog signaling pathway, which is often dysregulated in cancer cells."},{"drug_id":"daurismo","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Daurismo","generic_name":"Glasdegib Maleate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Smoothened (transmembrane protein)","drug_class":"Hedgehog pathway inhibitor","quality_score":10,"revenue":"150","mechanism":"Glasdegib inhibits Smoothened, a transmembrane protein in the Hedgehog signaling pathway."},{"drug_id":"gemtuzumab-ozogamicin","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mylotarg","generic_name":"gemtuzumab-ozogamicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Myeloid cell surface antigen CD33","drug_class":"CD33-directed Immunoconjugate [EPC]","quality_score":68,"revenue":"100","mechanism":"Mylotarg works by binding to CD33 on cancer cells and releasing a toxic compound that kills the cells."},{"drug_id":"mylotarg","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mylotarg","generic_name":"Gemtuzumab Ozogamicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD33 antigen","drug_class":"Antibody-drug conjugate (ADC)","quality_score":10,"revenue":"100","mechanism":"CD33-directed antibody-drug conjugate that delivers cytotoxic calicheamicin to tumor cells."},{"drug_id":"gemtuzumab","indication_name":"newly-diagnosed CD33-positive acute myeloid leukemia (AML)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mylotarg","generic_name":"GEMTUZUMAB","company_name":"Wyeth Pharms Inc","drug_phase":"marketed","molecular_target":"Myeloid cell surface antigen CD33","drug_class":"CD33-directed Immunoconjugate [EPC]","quality_score":10,"revenue":"100","mechanism":"Mylotarg targets and binds to CD33-positive cancer cells, delivering a cytotoxic agent to destroy them."},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic acute myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic acute lymphoblastic leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"chlorpromazine","indication_name":"Acute intermittent porphyria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Thorazine","generic_name":"chlorpromazine","company_name":"Generic (originally Rhône-Poulenc/Sanofi)","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, Sphingomyelin phosphodiesterase, 5-hydroxytryptamine receptor 1E","drug_class":"Typical antipsychotic (first-generation, phenothiazine)","quality_score":31,"revenue":null,"mechanism":""},{"drug_id":"xospata","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xospata","company_name":"French Innovative Leukemia Organisation","drug_phase":"marketed","molecular_target":"ADP/ATP translocase 2, ADP/ATP translocase 3, Bone morphogenetic protein receptor type-1B","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"panhematin","indication_name":"Acute intermittent porphyria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Panhematin","company_name":"Rush University Medical Center","drug_phase":"discontinued","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"oncovin","indication_name":"Acute lymphoid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Oncovin","company_name":"University of Colorado, Denver","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 7, Multidrug resistance protein 1","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"hydrocortisone-succinate","indication_name":"Acute lymphoid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Solu-Cortef","generic_name":"hydrocortisone succinate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"vincristin","indication_name":"Acute lymphoid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Vincristin","company_name":"Arbeitsgemeinschaft medikamentoese Tumortherapie","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 7, Multidrug resistance protein 1","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"neupogen","indication_name":"Refractory acute myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Neupogen","company_name":"University of Chicago","drug_phase":"marketed","molecular_target":"Granulocyte colony-stimulating factor receptor","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"neupogen","indication_name":"Relapsed acute myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Neupogen","company_name":"University of Chicago","drug_phase":"marketed","molecular_target":"Granulocyte colony-stimulating factor receptor","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"decitabine","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dacogen","generic_name":"decitabine","company_name":"Sun Pharma","drug_phase":"marketed","molecular_target":"DNA (cytosine-5)-methyltransferase 1","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":58,"revenue":null,"mechanism":"Dacogen works by inhibiting the enzyme that adds methyl groups to DNA, which helps to restore normal gene function in cancer cells."},{"drug_id":"daunorubicin","indication_name":"Acute lymphoid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Daunorubicin Hydrochloride","generic_name":"daunorubicin","company_name":"Meiji Seika Pharma Co., Ltd","drug_phase":"marketed","molecular_target":"Histone deacetylase 6","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"daunorubicin","indication_name":"Acute monocytic/monoblastic leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Daunorubicin Hydrochloride","generic_name":"daunorubicin","company_name":"Meiji Seika Pharma Co., Ltd","drug_phase":"marketed","molecular_target":"Histone deacetylase 6","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"daunorubicin","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Daunorubicin Hydrochloride","generic_name":"daunorubicin","company_name":"Meiji Seika Pharma Co., Ltd","drug_phase":"marketed","molecular_target":"Histone deacetylase 6","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"daunorubicin","indication_name":"Acute promyelocytic leukemia, FAB M3","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Daunorubicin Hydrochloride","generic_name":"daunorubicin","company_name":"Meiji Seika Pharma Co., Ltd","drug_phase":"marketed","molecular_target":"Histone deacetylase 6","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"revumenib","indication_name":"relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Revuforj","generic_name":"REVUMENIB","company_name":"Syndax","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Revuforj works by inhibiting an enzyme that is involved in the growth and survival of cancer cells."},{"drug_id":"revumenib","indication_name":"relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Revuforj","generic_name":"REVUMENIB","company_name":"Syndax","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Revuforj works by inhibiting an enzyme that is involved in the growth and survival of cancer cells."},{"drug_id":"azacitidine","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vidaza","generic_name":"azacitidine","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"DNA (cytosine-5)-methyltransferase 1","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":61,"revenue":null,"mechanism":"Vidaza works by incorporating itself into DNA and interfering with the enzyme that adds methyl groups, which helps to restore normal gene function in cancer cells."},{"drug_id":"hydrocortisone-acetate","indication_name":"Acute lymphoid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortifoam","generic_name":"HYDROCORTISONE ACETATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Malignant Cerebral Edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device and a Stentriever Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Stentriever Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Solitaire FR Revascularization Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Stentriever Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Stentriever Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Solitaire FR Revascularization Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Stentriever Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device and a Stentriever Device and a Trevo Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device and a Trevo Device and a Penumbra System","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Stentriever Device and a Trevo Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Stentriever Device and a Penumbra System","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Solitaire FR Revascularization Device and a Trevo Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Solitaire FR Revascularization Device and a Penumbra System","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Stentriever Device and a Trevo Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Stentriever Device and a Penumbra System","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device and a Stentriever Device and a Trevo Device and a Penumbra System","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device and a Stentriever Device and a Penumbra System","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device and a Trevo Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Stentriever Device and a Trevo Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"cortisone-acetate","indication_name":"Acute lymphoid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortone","generic_name":"CORTISONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"arsenic-trioxide","indication_name":"Acute myelomonocytic leukemia, FAB M4","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trisenox","generic_name":"ARSENIC TRIOXIDE","company_name":"Cephalon","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"High Risk QT Prolonging Agents","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"arsenic-trioxide","indication_name":"Acute promyelocytic leukemia, FAB M3","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trisenox","generic_name":"ARSENIC TRIOXIDE","company_name":"Cephalon","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"High Risk QT Prolonging Agents","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"quizartinib","indication_name":"Acute myeloid leukemia with FMS-like tyrosine kinase-3 mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vanflyta","generic_name":"QUIZARTINIB","company_name":"Daiichi Sankyo Inc","drug_phase":"marketed","molecular_target":"Macrophage colony-stimulating factor 1 receptor","drug_class":"","quality_score":75,"revenue":null,"mechanism":"Vanflyta works by blocking the macrophage colony-stimulating factor 1 receptor, which is involved in the growth and survival of cancer cells."},{"drug_id":"quizartinib","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vanflyta","generic_name":"QUIZARTINIB","company_name":"Daiichi Sankyo Inc","drug_phase":"marketed","molecular_target":"Macrophage colony-stimulating factor 1 receptor","drug_class":"","quality_score":75,"revenue":null,"mechanism":"Vanflyta works by blocking the macrophage colony-stimulating factor 1 receptor, which is involved in the growth and survival of cancer cells."},{"drug_id":"fludarabine-phosphate","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fludara","generic_name":"FLUDARABINE PHOSPHATE","company_name":"Nihon Schering K.K.","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 5A, mitochondrial","drug_class":"Nucleoside Metabolic Inhibitor","quality_score":65,"revenue":null,"mechanism":"Fludara works by interfering with the production of DNA and RNA in cancer cells, ultimately leading to cell death."},{"drug_id":"betamethasone-acetate","indication_name":"Acute lymphoid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Celestone Soluspan","generic_name":"BETAMETHASONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone","indication_name":"Acute lymphoid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"hemin","indication_name":"Acute intermittent porphyria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Normosang","generic_name":"HEMIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":45,"revenue":null,"mechanism":"Normosang replenishes heme, a crucial component in hemoglobin production, to treat Acute Intermittent Porphyria."},{"drug_id":"bhv-3500-zavegepant","indication_name":"Acute migraine treatment","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BHV-3500 (zavegepant)","generic_name":"bhv-3500-zavegepant","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"CGRP receptor (calcitonin gene-related peptide receptor)","drug_class":"CGRP receptor antagonist","quality_score":30,"revenue":null,"mechanism":"Zavegepant is a CGRP receptor antagonist that blocks neuropeptide signaling to reduce migraine pain and associated symptoms."},{"drug_id":"bhv-3500-zavegepant","indication_name":"Acute migraine treatment","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BHV-3500 (zavegepant)","generic_name":"bhv-3500-zavegepant","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"CGRP receptor (calcitonin gene-related peptide receptor)","drug_class":"CGRP receptor antagonist","quality_score":30,"revenue":null,"mechanism":"Zavegepant is a CGRP receptor antagonist that blocks neuropeptide signaling to reduce migraine pain and associated symptoms."},{"drug_id":"vindesin","indication_name":"Acute lymphoid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Vindesin","company_name":"The Lymphoma Academic Research Organisation","drug_phase":"discontinued","molecular_target":"Cytochrome P450 3A4","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"idarubicin-hydrochloride","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Idamycin Pfs","generic_name":"Idarubicin Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"DNA, Topoisomerase II","drug_class":"Anthracycline topoisomerase inhibitor","quality_score":61,"revenue":null,"mechanism":"Idarubicin forms DNA complexes, inhibits nucleic acid synthesis and topoisomerase II, produces DNA-damaging free radicals."},{"drug_id":"idarubicin-hydrochloride","indication_name":"Acute promyelocytic leukemia, FAB M3","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Idamycin Pfs","generic_name":"Idarubicin Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"DNA, Topoisomerase II","drug_class":"Anthracycline topoisomerase inhibitor","quality_score":61,"revenue":null,"mechanism":"Idarubicin forms DNA complexes, inhibits nucleic acid synthesis and topoisomerase II, produces DNA-damaging free radicals."},{"drug_id":"calaspargase","indication_name":"Acute Lymphoblastic Leukemia (ALL) in pediatric and adult patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Asparlas","generic_name":"calaspargase","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"L-asparagine","drug_class":"Asparagine-specific Enzyme [EPC]","quality_score":50,"revenue":null,"mechanism":"Calaspargase is an L-asparaginase enzyme that catalyzes the conversion of L-asparagine into aspartic acid and ammonia, leading to the depletion of plasma asparagine and the death of leukemic cells."},{"drug_id":"calaspargase","indication_name":"Acute Lymphoblastic Leukemia (ALL) in pediatric patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Asparlas","generic_name":"calaspargase","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"L-asparagine","drug_class":"Asparagine-specific Enzyme [EPC]","quality_score":50,"revenue":null,"mechanism":"Calaspargase is an L-asparaginase enzyme that catalyzes the conversion of L-asparagine into aspartic acid and ammonia, leading to the depletion of plasma asparagine and the death of leukemic cells."},{"drug_id":"dacogen","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Dacogen","company_name":"Mayo Clinic","drug_phase":"discontinued","molecular_target":"DNA (cytosine-5)-methyltransferase 1, DNA (cytosine-5)-methyltransferase 3A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"daunorubicine","indication_name":"Acute lymphoid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Daunorubicine","company_name":"Gruppo Italiano Malattie EMatologiche dell'Adulto","drug_phase":"discontinued","molecular_target":"Multidrug resistance-associated protein 6, 72 kDa type IV collagenase, ATP-binding cassette sub-family G member 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"daunorubicine","indication_name":"Acute monocytic/monoblastic leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Daunorubicine","company_name":"Gruppo Italiano Malattie EMatologiche dell'Adulto","drug_phase":"discontinued","molecular_target":"Multidrug resistance-associated protein 6, 72 kDa type IV collagenase, ATP-binding cassette sub-family G member 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"daunorubicine","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Daunorubicine","company_name":"Gruppo Italiano Malattie EMatologiche dell'Adulto","drug_phase":"discontinued","molecular_target":"Multidrug resistance-associated protein 6, 72 kDa type IV collagenase, ATP-binding cassette sub-family G member 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"daunorubicine","indication_name":"Acute promyelocytic leukemia, FAB M3","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Daunorubicine","company_name":"Gruppo Italiano Malattie EMatologiche dell'Adulto","drug_phase":"discontinued","molecular_target":"Multidrug resistance-associated protein 6, 72 kDa type IV collagenase, ATP-binding cassette sub-family G member 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"histamine","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Eramin","generic_name":"HISTAMINE","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Histamine H3 receptor","drug_class":"histamine","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"oral-p2y12-receptor-blocker","indication_name":"Prevention of atherothrombotic events in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Oral P2Y12 receptor blocker","company_name":"Italian Society of Invasive Cardiology","drug_phase":"marketed","molecular_target":"P2Y12 adenosine diphosphate receptor on platelet surface","drug_class":"Antiplatelet agent; P2Y12 receptor antagonist; Thienopyridine or non-thienopyridine class","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"doxorubicin-hydrochloride","indication_name":"Acute lymphoblastic leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Doxorubicin Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"DNA topoisomerase II, nucleotide bases","drug_class":"Anthracycline topoisomerase inhibitor","quality_score":70,"revenue":null,"mechanism":"Doxorubicin intercalates nucleotide bases and interacts with topoisomerase II to form DNA-cleavable complexes, inhibiting DNA/RNA replication."},{"drug_id":"doxorubicin-hydrochloride","indication_name":"Acute myeloblastic leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Doxorubicin Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"DNA topoisomerase II, nucleotide bases","drug_class":"Anthracycline topoisomerase inhibitor","quality_score":70,"revenue":null,"mechanism":"Doxorubicin intercalates nucleotide bases and interacts with topoisomerase II to form DNA-cleavable complexes, inhibiting DNA/RNA replication."},{"drug_id":"no-oac","indication_name":"Acute Ischemic Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"cytarabine","indication_name":"Acute lymphoid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytarabine","generic_name":"Cytarabine","company_name":"Nippon Shinyaku Co., Ltd.","drug_phase":"marketed","molecular_target":"DNA polymerase","drug_class":"Antimetabolite","quality_score":72,"revenue":null,"mechanism":"Cytarabine inhibits DNA polymerase and incorporates into DNA/RNA, killing cells in S-phase."},{"drug_id":"cytarabine","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytarabine","generic_name":"Cytarabine","company_name":"Nippon Shinyaku Co., Ltd.","drug_phase":"marketed","molecular_target":"DNA polymerase","drug_class":"Antimetabolite","quality_score":72,"revenue":null,"mechanism":"Cytarabine inhibits DNA polymerase and incorporates into DNA/RNA, killing cells in S-phase."},{"drug_id":"cytarabine","indication_name":"Acute promyelocytic leukemia, FAB M3","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytarabine","generic_name":"Cytarabine","company_name":"Nippon Shinyaku Co., Ltd.","drug_phase":"marketed","molecular_target":"DNA polymerase","drug_class":"Antimetabolite","quality_score":72,"revenue":null,"mechanism":"Cytarabine inhibits DNA polymerase and incorporates into DNA/RNA, killing cells in S-phase."},{"drug_id":"6-mercaptopurine","indication_name":"Acute lymphoid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-Mercaptopurine","generic_name":"6-mercaptopurine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Multidrug resistance-associated protein 4, Multidrug resistance-associated protein 5, Thiopurine S-methyltransferase","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"6-mercaptopurine","indication_name":"Acute promyelocytic leukemia, FAB M3","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-Mercaptopurine","generic_name":"6-mercaptopurine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Multidrug resistance-associated protein 4, Multidrug resistance-associated protein 5, Thiopurine S-methyltransferase","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"gleevec","indication_name":"Philadelphia chromosome-positive acute lymphoblastic leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Gleevec","company_name":"M.D. Anderson Cancer Center","drug_phase":"marketed","molecular_target":"Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, ATP-binding cassette sub-family G member 2, ATP-dependent RNA helicase DDX3X","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"rimegepant-for-acute-migraine-treatment","indication_name":"Acute treatment of migraine with or without aura in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimegepant for acute migraine treatment","generic_name":"rimegepant-for-acute-migraine-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"calcitonin gene-related peptide receptor","drug_class":"calcitonin gene-related peptide receptor antagonist","quality_score":54,"revenue":null,"mechanism":"Rimegepant targets the calcitonin gene-related peptide receptor to treat acute migraine."},{"drug_id":"adriacin","indication_name":"Acute lymphoid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"adriacin","company_name":"Chipscreen Biosciences, Ltd.","drug_phase":"phase_1","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"adriacin","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"adriacin","company_name":"Chipscreen Biosciences, Ltd.","drug_phase":"phase_1","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"tretinoin","indication_name":"Acute promyelocytic leukemia, FAB M3","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Retin-A","generic_name":"TRETINOIN","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Nuclear receptor ROR-beta","drug_class":"Retinoid [EPC]","quality_score":58,"revenue":null,"mechanism":"Tretinoin works by binding to and activating nuclear receptors, which helps to regulate cell growth and differentiation."},{"drug_id":"hydroxydaunorubicin","indication_name":"Acute lymphoid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunorubicin","company_name":"University of Colorado, Denver","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hydroxydaunorubicin","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunorubicin","company_name":"University of Colorado, Denver","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"aclacinomycin","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"aclacinomycin","company_name":"Chinese PLA General Hospital","drug_phase":"phase_3","molecular_target":"72 kDa type IV collagenase, DNA topoisomerase II, 5-hydroxytryptamine receptor 2B","drug_class":"","quality_score":4,"revenue":null,"mechanism":null},{"drug_id":"erwinase","indication_name":"Acute lymphoid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Erwinase","company_name":"M.D. Anderson Cancer Center","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"cyclophosphamid","indication_name":"Acute lymphoid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cyclophosphamid","company_name":"Zhejiang University","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"cyclophosphamid","indication_name":"Acute monocytic leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cyclophosphamid","company_name":"Zhejiang University","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"cyclophosphamid","indication_name":"Acute myelogenous leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cyclophosphamid","company_name":"Zhejiang University","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"enasidenib","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Idhifa","generic_name":"ENASIDENIB","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Isocitrate dehydrogenase [NADP], mitochondrial","drug_class":"Isocitrate Dehydrogenase 2 Inhibitor","quality_score":59,"revenue":null,"mechanism":"Idhifa works by blocking the IDH2 enzyme, which is mutated in some AML cells, to prevent the production of a toxic metabolite that promotes cancer growth."},{"drug_id":"azacytidine","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"azacytidine","company_name":"Assistance Publique Hopitaux De Marseille","drug_phase":"marketed","molecular_target":"DNA (cytosine-5)-methyltransferase 1, DNA (cytosine-5)-methyltransferase 3A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"oncaspar","indication_name":"Acute lymphoid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Oncaspar","company_name":"Dana-Farber Cancer Institute","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":9,"revenue":null,"mechanism":null},{"drug_id":"prednison","indication_name":"Acute lymphoid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednison","company_name":"Wen Zhang","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"trisenox","indication_name":"Acute myelomonocytic leukemia, FAB M4","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Trisenox","company_name":"German AML Cooperative Group","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2, Thioredoxin reductase 1, cytoplasmic","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"trisenox","indication_name":"Acute promyelocytic leukemia, FAB M3","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Trisenox","company_name":"German AML Cooperative Group","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2, Thioredoxin reductase 1, cytoplasmic","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"rimegepant-75mg-orally-disintegrating-tablets-odt","indication_name":"Acute treatment of migraine attacks with or without aura in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimegepant 75mg Orally Disintegrating Tablets (ODT)","generic_name":"rimegepant-75mg-orally-disintegrating-tablets-odt","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"calcitonin gene-related peptide receptor","drug_class":"calcitonin gene-related peptide receptor antagonist","quality_score":51,"revenue":null,"mechanism":"Rimegepant is a calcitonin gene-related peptide receptor antagonist."},{"drug_id":"methylprednisolone","indication_name":"Acute lymphoid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Medrol","generic_name":"methylprednisolone","company_name":"Generic (originally Upjohn/Pfizer)","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"Glucocorticoid (corticosteroid)","quality_score":62,"revenue":null,"mechanism":"Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions."},{"drug_id":"rimegepant-75mg-daily-dosing","indication_name":"Acute treatment of migraine attacks with or without aura in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimegepant 75mg daily dosing","generic_name":"rimegepant-75mg-daily-dosing","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"calcitonin gene-related peptide receptor","drug_class":"calcitonin gene-related peptide receptor antagonist","quality_score":53,"revenue":null,"mechanism":"Rimegepant is a calcitonin gene-related peptide receptor antagonist that inhibits the release of pro-inflammatory peptides."},{"drug_id":"hydrocortisone","indication_name":"Acute lymphoid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortef","generic_name":"hydrocortisone","company_name":"Generic (originally Merck/Upjohn)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"vindesine","indication_name":"Acute lymphoid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Eldisine","generic_name":"VINDESINE","company_name":"","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"vindesine","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"aclarubicin","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aclacur","generic_name":"ACLARUBICIN","company_name":"","drug_phase":"phase_3","molecular_target":"5-hydroxytryptamine receptor 2B","drug_class":"aclarubicin","quality_score":null,"revenue":null,"mechanism":"Aclacur works by binding to the 5-hydroxytryptamine receptor 2B, which is involved in cell growth and proliferation."},{"drug_id":"mitoxantrone","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novantrone","generic_name":"MITOXANTRONE","company_name":"","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase pim-1","drug_class":"Topoisomerase Inhibitor","quality_score":71,"revenue":null,"mechanism":"Novantrone works by interfering with the enzyme topoisomerase, which is necessary for DNA replication and cell division."},{"drug_id":"part-c-met097","indication_name":"Treatment of Acute Myeloid Leukemia (AML)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"(Part C) MET097","generic_name":"part-c-met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":37,"revenue":null,"mechanism":"The exact mechanism of action is not specified on Wikipedia."},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of acute myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"triamcinolone","indication_name":"Acute lymphoid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rodinolone","generic_name":"TRIAMCINOLONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"prednisone","indication_name":"Acute lymphoid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"thioguanine","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Thioguanine","generic_name":"thioguanine","company_name":"Waylis","drug_phase":"marketed","molecular_target":"Prostaglandin G/H synthase 1","drug_class":"thioguanine","quality_score":57,"revenue":null,"mechanism":""},{"drug_id":"crisantaspase","indication_name":"Acute lymphoid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Erwinase","generic_name":"CRISANTASPASE","company_name":"Jazz Pharms Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":15,"revenue":null,"mechanism":""},{"drug_id":"rimegepant-bhv3000","indication_name":"Acute treatment of migraine with or without aura in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimegepant/BHV3000","generic_name":"rimegepant-bhv3000","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"calcitonin gene-related peptide receptor (CGRPR)","drug_class":"pharmacological class not specified","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"ziftomenib","indication_name":"relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Komzifti","generic_name":"ZIFTOMENIB","company_name":"Kura","drug_phase":"marketed","molecular_target":"","drug_class":"Menin Inhibitor [EPC]","quality_score":60,"revenue":null,"mechanism":"Komzifti works by inhibiting the menin protein, which is involved in the regulation of gene expression in cancer cells."},{"drug_id":"ziftomenib","indication_name":"relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Komzifti","generic_name":"ZIFTOMENIB","company_name":"Kura","drug_phase":"marketed","molecular_target":"","drug_class":"Menin Inhibitor [EPC]","quality_score":60,"revenue":null,"mechanism":"Komzifti works by inhibiting the menin protein, which is involved in the regulation of gene expression in cancer cells."},{"drug_id":"rimegepant-25-mg","indication_name":"Acute treatment of migraine with or without aura in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimegepant 25 MG","generic_name":"rimegepant-25-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"calcitonin gene-related peptide receptor","drug_class":"calcitonin gene-related peptide receptor antagonist","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Acute Ischemic Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"mercaptopurine","indication_name":"Acute lymphoid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Purixan","generic_name":"MERCAPTOPURINE","company_name":"Stason Pharms","drug_phase":"marketed","molecular_target":"Prostaglandin G/H synthase 1","drug_class":"mercaptopurine","quality_score":62,"revenue":null,"mechanism":"Purixan works by inhibiting the enzyme responsible for producing prostaglandins, which are involved in inflammation and immune response."},{"drug_id":"mercaptopurine","indication_name":"Acute promyelocytic leukemia, FAB M3","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Purixan","generic_name":"MERCAPTOPURINE","company_name":"Stason Pharms","drug_phase":"marketed","molecular_target":"Prostaglandin G/H synthase 1","drug_class":"mercaptopurine","quality_score":62,"revenue":null,"mechanism":"Purixan works by inhibiting the enzyme responsible for producing prostaglandins, which are involved in inflammation and immune response."},{"drug_id":"vincristine-sulfate-pfs","indication_name":"Acute lymphoid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Oncovin","generic_name":"Vincristine Sulfate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1","drug_class":"Vinca Alkaloid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"chembl-chembl1200976","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Idamycin Pfs","generic_name":"IDARUBICIN HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"DNA, topoisomerase II","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":75,"revenue":null,"mechanism":"Idarubicin hydrochloride exerts its effects by forming DNA complexes, inhibiting nucleic acid synthesis, blocking topoisomerase II, and generating DNA-damaging free radicals."},{"drug_id":"chembl-chembl1200976","indication_name":"Acute promyelocytic leukemia, FAB M3","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Idamycin Pfs","generic_name":"IDARUBICIN HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"DNA, topoisomerase II","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":75,"revenue":null,"mechanism":"Idarubicin hydrochloride exerts its effects by forming DNA complexes, inhibiting nucleic acid synthesis, blocking topoisomerase II, and generating DNA-damaging free radicals."},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Solitaire FR Revascularization Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Trevo Retriever","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Trevo Retriever 3D","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Trevo XP","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Trevo XP ProVue","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Catheter","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Catheter with Xtreem Micro Guidewire","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"imatinib","indication_name":"Philadelphia chromosome-positive acute lymphoblastic leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gleevec","generic_name":"imatinib","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"Kinase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Gleevec works by blocking the activity of specific enzymes involved in cancer cell growth and proliferation."},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"prednisone","indication_name":"Acute leukemia of childhood","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tisagenlecleucel","indication_name":"B-cell precursor acute lymphoblastic leukemia (ALL)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kymriah","generic_name":"TISAGENLECLEUCEL","company_name":"Novartis Pharmaceuticals Corporation","drug_phase":"marketed","molecular_target":"","drug_class":"CD19-directed Chimeric Antigen Receptor [EPC]","quality_score":50,"revenue":null,"mechanism":"Kymriah modifies a patient's T-cells to recognize and attack cancer cells expressing the CD19 protein."},{"drug_id":"tisagenlecleucel","indication_name":"B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kymriah","generic_name":"TISAGENLECLEUCEL","company_name":"Novartis Pharmaceuticals Corporation","drug_phase":"marketed","molecular_target":"","drug_class":"CD19-directed Chimeric Antigen Receptor [EPC]","quality_score":50,"revenue":null,"mechanism":"Kymriah modifies a patient's T-cells to recognize and attack cancer cells expressing the CD19 protein."},{"drug_id":"ivosidenib","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tibsovo","generic_name":"IVOSIDENIB","company_name":"Servier","drug_phase":"marketed","molecular_target":"mutant IDH1","drug_class":"Isocitrate Dehydrogenase 1 Inhibitor [EPC]","quality_score":70,"revenue":null,"mechanism":"Ivosidenib inhibits mutant IDH1, reducing 2-HG levels and promoting myeloid differentiation in AML."},{"drug_id":"vincristine","indication_name":"Acute lymphoid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Oncovin","generic_name":"vincristine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1","drug_class":"Vinca Alkaloid","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"aldesleukin","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Proleukin","generic_name":"ALDESLEUKIN","company_name":"Chiron","drug_phase":"marketed","molecular_target":"Interleukin-2 receptor","drug_class":"Lymphocyte Growth Factor [EPC]","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"liposomal-doxorubicin","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Liposomal Doxorubicin","generic_name":"liposomal-doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase","drug_class":"doxorubicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"triptans","indication_name":"Acute treatment of migraine attacks with or without aura in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Triptans","generic_name":"triptans","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Serotonin 5-HT1B/1D receptors","drug_class":"Selective serotonin receptor agonists","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"liposomal-doxorubicin","indication_name":"Acute lymphoid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Liposomal Doxorubicin","generic_name":"liposomal-doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase","drug_class":"doxorubicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"calaspargase-pegol","indication_name":"Acute lymphoblastic leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Asparlas","generic_name":"CALASPARGASE PEGOL","company_name":"Servier Pharma Llc ","drug_phase":"marketed","molecular_target":"","drug_class":"Asparagine-specific Enzyme [EPC]","quality_score":10,"revenue":null,"mechanism":"Asparlas depletes asparagine, an amino acid that cancer cells rely on for growth."},{"drug_id":"rimegepant-75-mg-odt","indication_name":"Acute treatment of migraine with or without aura in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"rimegepant 75 mg ODT","generic_name":"rimegepant-75-mg-odt","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CGRP receptors","drug_class":"CGRP receptor antagonist","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"nelarabine","indication_name":"T-cell acute lymphoblastic leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arranon","generic_name":"NELARABINE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":75,"revenue":null,"mechanism":"Arranon works by inhibiting the enzyme responsible for converting nucleosides into their active forms, thereby preventing DNA synthesis in cancer cells."},{"drug_id":"clofarabine","indication_name":"Acute lymphoid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Clolar","generic_name":"CLOFARABINE","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Ribonucleoside-diphosphate reductase large subunit","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":70,"revenue":null,"mechanism":"Clolar works by inhibiting the enzyme responsible for DNA synthesis, thereby preventing cancer cells from reproducing."},{"drug_id":"olutasidenib","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rezlidhia","generic_name":"OLUTASIDENIB","company_name":"Rigel Pharms","drug_phase":"marketed","molecular_target":"mutated IDH1","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Olutasidenib inhibits mutated IDH1, reducing 2-HG levels in AML cells."},{"drug_id":"olutasidenib","indication_name":"Refractory acute myeloid leukemia with a susceptible IDH1 mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rezlidhia","generic_name":"OLUTASIDENIB","company_name":"Rigel Pharms","drug_phase":"marketed","molecular_target":"mutated IDH1","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Olutasidenib inhibits mutated IDH1, reducing 2-HG levels in AML cells."},{"drug_id":"olutasidenib","indication_name":"Relapsing acute myeloid leukemia with a susceptible IDH1 mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rezlidhia","generic_name":"OLUTASIDENIB","company_name":"Rigel Pharms","drug_phase":"marketed","molecular_target":"mutated IDH1","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Olutasidenib inhibits mutated IDH1, reducing 2-HG levels in AML cells."},{"drug_id":"betamethasone","indication_name":"Acute lymphoid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betametasone","generic_name":"BETAMETHASONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":65,"revenue":null,"mechanism":"Betamethasone works by binding to the glucocorticoid receptor, which then triggers a series of downstream effects that reduce inflammation and suppress the immune system."},{"drug_id":"doxorubicin","indication_name":"Acute lymphoid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Doxorubicin Hydrochloride","generic_name":"doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aurora kinase A","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA strands and inhibiting topoisomerase II, an enzyme essential for DNA replication and cell division."},{"drug_id":"doxorubicin","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Doxorubicin Hydrochloride","generic_name":"doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aurora kinase A","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA strands and inhibiting topoisomerase II, an enzyme essential for DNA replication and cell division."},{"drug_id":"idarubicin","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Idamycin Pfs","generic_name":"IDARUBICIN","company_name":"","drug_phase":"marketed","molecular_target":"DNA topoisomerase 2-alpha","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":70,"revenue":null,"mechanism":"Idarubicin works by binding to DNA topoisomerase 2-alpha, preventing the enzyme from unwinding DNA and leading to cell death."},{"drug_id":"idarubicin","indication_name":"Acute promyelocytic leukemia, FAB M3","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Idamycin Pfs","generic_name":"IDARUBICIN","company_name":"","drug_phase":"marketed","molecular_target":"DNA topoisomerase 2-alpha","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":70,"revenue":null,"mechanism":"Idarubicin works by binding to DNA topoisomerase 2-alpha, preventing the enzyme from unwinding DNA and leading to cell death."},{"drug_id":"chembl-chembl1200796","indication_name":"Acute lymphoid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytoxan (Lyophilized)","generic_name":"CYCLOPHOSPHAMIDE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"cyclophosphamide","quality_score":10,"revenue":null,"mechanism":"Cytoxan works by interfering with the DNA replication process in rapidly dividing cancer cells."},{"drug_id":"chembl-chembl1200796","indication_name":"Acute monocytic leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytoxan (Lyophilized)","generic_name":"CYCLOPHOSPHAMIDE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"cyclophosphamide","quality_score":10,"revenue":null,"mechanism":"Cytoxan works by interfering with the DNA replication process in rapidly dividing cancer cells."},{"drug_id":"chembl-chembl1200796","indication_name":"Acute myelogenous leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytoxan (Lyophilized)","generic_name":"CYCLOPHOSPHAMIDE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"cyclophosphamide","quality_score":10,"revenue":null,"mechanism":"Cytoxan works by interfering with the DNA replication process in rapidly dividing cancer cells."},{"drug_id":"methotrexate","indication_name":"Acute lymphoid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trexall","generic_name":"methotrexate","company_name":"Generic (originally Lederle Laboratories)","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, High mobility group protein B1, Multidrug resistance-associated protein 4","drug_class":"Antifolate, DMARD","quality_score":55,"revenue":null,"mechanism":"Antifolate that inhibits dihydrofolate reductase (DHFR), blocking DNA synthesis at high doses (oncology) and suppressing inflammation at low doses (autoimmune)."},{"drug_id":"fludarabin","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fludarabin","company_name":"Azienda Ospedaliera San Giovanni Battista","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 5A, mitochondrial, DNA polymerase alpha catalytic subunit, Ribonucleoside-diphosphate reductase large subunit","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"methotrexat","indication_name":"Acute lymphoid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methotrexat","company_name":"Biocad","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, High mobility group protein B1, Multidrug resistance-associated protein 4","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cortisol","indication_name":"Acute lymphoid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cortisol","company_name":"University of Zurich","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolone","indication_name":"Acute lymphoid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prelone","generic_name":"prednisolone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"Glucocorticoid (corticosteroid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"hydroxydaunomycin","indication_name":"Acute lymphoid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunomycin","company_name":"Weill Medical College of Cornell University","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hydroxydaunomycin","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunomycin","company_name":"Weill Medical College of Cornell University","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"proleukin","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Proleukin","company_name":"University of Minnesota","drug_phase":"marketed","molecular_target":"Interleukin-2 receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"fludara","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fludara","company_name":"Celyad Oncology SA","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 5A, mitochondrial, DNA polymerase alpha catalytic subunit, Ribonucleoside-diphosphate reductase large subunit","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolon","indication_name":"Acute lymphoid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednisolon","company_name":"Hannover Medical School","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"adriamycin","indication_name":"Acute lymphoid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Adriamycin","company_name":"Johann Wolfgang Goethe University Hospital","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"adriamycin","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Adriamycin","company_name":"Johann Wolfgang Goethe University Hospital","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"methylprednisolon","indication_name":"Acute lymphoid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methylprednisolon","company_name":"Leiden University Medical Center","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"xaluprine","indication_name":"Acute lymphoid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xaluprine","company_name":"Kjeld Schmiegelow","drug_phase":"marketed","molecular_target":"Multidrug resistance-associated protein 4, Multidrug resistance-associated protein 5, Thiopurine S-methyltransferase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"xaluprine","indication_name":"Acute promyelocytic leukemia, FAB M3","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xaluprine","company_name":"Kjeld Schmiegelow","drug_phase":"marketed","molecular_target":"Multidrug resistance-associated protein 4, Multidrug resistance-associated protein 5, Thiopurine S-methyltransferase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"mitozantrone","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Mitozantrone","company_name":"US Department of Veterans Affairs","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, ATP-binding cassette sub-family G member 2, DNA-(apurinic or apyrimidinic site) lyase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"vincristine-sulfate-pfs","indication_name":"Acute leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Oncovin","generic_name":"Vincristine Sulfate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1","drug_class":"Vinca Alkaloid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"samidorphan","indication_name":"Bipolar I Disorder - Acute Manic or Mixed Episodes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lybalvi","generic_name":"SAMIDORPHAN","company_name":"Alkermes Inc","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Atypical Antipsychotic [EPC]","quality_score":10,"revenue":null,"mechanism":"Lybalvi blocks the action of opioids at their receptor sites in the brain."},{"drug_id":"hemin","indication_name":"Acute Intermittent Porphyria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Normosang","generic_name":"HEMIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":45,"revenue":null,"mechanism":"Normosang replenishes heme, a crucial component in hemoglobin production, to treat Acute Intermittent Porphyria."},{"drug_id":"idarubicin","indication_name":"Acute Myeloid Leukemia (AML)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Idamycin Pfs","generic_name":"IDARUBICIN","company_name":"","drug_phase":"marketed","molecular_target":"DNA topoisomerase 2-alpha","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":70,"revenue":null,"mechanism":"Idarubicin works by binding to DNA topoisomerase 2-alpha, preventing the enzyme from unwinding DNA and leading to cell death."},{"drug_id":"dexamethasone-phosphate","indication_name":"Acute leukemia of childhood","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexamethasone Sodium Phosphate","generic_name":"dexamethasone phosphate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Androgen receptor, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"daunorubicin-hydrochloride","indication_name":"Remission induction in pediatric and adult acute lymphocytic leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DAUNORUBICIN HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"zolmitriptan","indication_name":"Acute treatment of migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zomig","generic_name":"ZOLMITRIPTAN","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1D","drug_class":"Serotonin-1b and Serotonin-1d Receptor Agonist [EPC]","quality_score":75,"revenue":null,"mechanism":"Zolmitriptan works by binding to serotonin receptors in the brain to constrict blood vessels and block pain pathways."},{"drug_id":"daunorubicin-hydrochloride","indication_name":"Remission induction in adult acute nonlymphocytic leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DAUNORUBICIN HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"mitoxantrone","indication_name":"Acute Nonlymphocytic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novantrone","generic_name":"MITOXANTRONE","company_name":"","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase pim-1","drug_class":"Topoisomerase Inhibitor","quality_score":71,"revenue":null,"mechanism":"Novantrone works by interfering with the enzyme topoisomerase, which is necessary for DNA replication and cell division."},{"drug_id":"eletriptan-hydrobromide","indication_name":"Acute treatment of migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ELETRIPTAN HYDROBROMIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"eletriptan","indication_name":"Acute treatment of migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Relpax","generic_name":"ELETRIPTAN","company_name":"Upjohn","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1D","drug_class":"Serotonin-1b and Serotonin-1d Receptor Agonist","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"samidorphan-l-malate","indication_name":"Bipolar I Disorder - Acute Manic or Mixed Episodes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SAMIDORPHAN L-MALATE","company_name":"","drug_phase":"marketed","molecular_target":"dopamine and serotonin type 2 (5HT2) receptors, opioid receptors","drug_class":"Atypical Antipsychotic [EPC]","quality_score":10,"revenue":null,"mechanism":"Olanzapine's efficacy may be due to dopamine and serotonin type 2 antagonism, while samidorphan acts through opioid receptor antagonism."},{"drug_id":"sodium-phenylacetate","indication_name":"Acute hyperammonemia and associated encephalopathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SODIUM PHENYLACETATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":45,"revenue":null,"mechanism":"Sodium phenylacetate and sodium benzoate provide alternative pathways for nitrogen disposal in patients with urea cycle disorders."},{"drug_id":"chembl-chembl359744","indication_name":"Acute Lymphoblastic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DOXORUBICIN HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"topoisomerase II","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA, inhibiting nucleotide replication, and forming DNA-cleavable complexes with topoisomerase II."},{"drug_id":"chembl-chembl359744","indication_name":"Acute Myeloblastic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DOXORUBICIN HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"topoisomerase II","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA, inhibiting nucleotide replication, and forming DNA-cleavable complexes with topoisomerase II."},{"drug_id":"naratriptan","indication_name":"Acute treatment of migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Amerge","generic_name":"NARATRIPTAN","company_name":"GSK","drug_phase":"marketed","molecular_target":"5-HT 1B/1D receptors","drug_class":"Serotonin-1b and Serotonin-1d Receptor Agonist","quality_score":75,"revenue":null,"mechanism":"Naratriptan treats migraines by binding to 5-HT 1B/1D receptors, causing cranial vessel constriction and inhibiting neuropeptide release."},{"drug_id":"rizatriptan-benzoate","indication_name":"Acute treatment of migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"RIZATRIPTAN BENZOATE","company_name":"","drug_phase":"marketed","molecular_target":"5-HT 1B/1D receptors","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Rizatriptan treats migraines by binding to 5-HT 1B/1D receptors on blood vessels and nerves."},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""}],"pipeline":[{"drug_id":"bhv-3500-zavegepant","indication_name":"Acute migraine","indication_type":"pipeline","phase":"Phase 3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BHV-3500 (zavegepant)","generic_name":"bhv-3500-zavegepant","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"CGRP receptor (calcitonin gene-related peptide receptor)","drug_class":"CGRP receptor antagonist","quality_score":30,"revenue":null,"mechanism":"Zavegepant is a CGRP receptor antagonist that blocks neuropeptide signaling to reduce migraine pain and associated symptoms."},{"drug_id":"rimegepant-75-mg","indication_name":"Acute treatment of migraine with or without aura","indication_type":"pipeline","phase":"Phase 3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimegepant 75 MG","generic_name":"rimegepant-75-mg","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"Calcitonin gene-related peptide (CGRP) receptor","drug_class":"CGRP receptor antagonist (gepant)","quality_score":25,"revenue":null,"mechanism":"Rimegepant selectively antagonizes the calcitonin gene-related peptide (CGRP) receptor to block migraine pain signaling."},{"drug_id":"rimegepant-75-mg","indication_name":"Acute treatment of migraine in pediatric subjects","indication_type":"pipeline","phase":"Phase 3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimegepant 75 MG","generic_name":"rimegepant-75-mg","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"Calcitonin gene-related peptide (CGRP) receptor","drug_class":"CGRP receptor antagonist (gepant)","quality_score":25,"revenue":null,"mechanism":"Rimegepant selectively antagonizes the calcitonin gene-related peptide (CGRP) receptor to block migraine pain signaling."}],"offLabel":[],"totalMarketed":321,"totalPipeline":3},"trials":{"data":[{"nct_id":"NCT05198492","title":"Short- and Long-term Health Effects of Air Pollution in Poland","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":8300000,"lead_sponsor_name":"Medical University of Bialystok","has_results":false},{"nct_id":"NCT03699137","title":"Pre-hospital ECG in Acute Coronary Syndromes","phase":"","overall_status":"COMPLETED","enrollment_count":420048,"lead_sponsor_name":"Kingston University","has_results":false},{"nct_id":"NCT07416617","title":"Impact of New-onset Insomnia After Coronary Revascularization for Patients With Acute Myocardial Infarction","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":235342,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT07198191","title":"SGLT2 Inhibitor Use After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Nationwide Cohort Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":200000,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT07163767","title":"Acute Myocardial Infarction Prediction Using Artificial Intelligence Applied to Electrocardiogram Images","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":150000,"lead_sponsor_name":"Guangdong Provincial People's Hospital","has_results":false},{"nct_id":"NCT04192175","title":"Identification of Patients Admitted With COPD Exacerbations and Predicting Readmission Risk Using Machine Learning","phase":"","overall_status":"COMPLETED","enrollment_count":65000,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT05649384","title":"Emergency Department Triage of Patients With Acute Chest Pain Based on the ESC 0/1-hour Algorithm (PRESC1SE-MI)","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":64374,"lead_sponsor_name":"University Hospital, Basel, Switzerland","has_results":false},{"nct_id":"NCT03258983","title":"Alpha-linolenic Acid and the Risk of ASCVD","phase":"","overall_status":"COMPLETED","enrollment_count":57053,"lead_sponsor_name":"Aalborg University Hospital","has_results":false},{"nct_id":"NCT06976723","title":"Nerivio Efficacy by Time of Treatment Onset","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":55261,"lead_sponsor_name":"Theranica","has_results":false},{"nct_id":"NCT06628817","title":"The Intensive Care Bundle with Mortality Reduction in Acute Ischemic Stroke Trial","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":55000,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT05779215","title":"Registry of Acute Ischemic Stroke With Large- or Medium-vessel Occlusion","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"Xuanwu Hospital, Beijing","has_results":false},{"nct_id":"NCT03629977","title":"Timing of Renal Replacement Therapy in the Critically Ill Patients","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"Karolinska University Hospital","has_results":false},{"nct_id":"NCT01252485","title":"Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - The Biology and Outcome (BiO)-Project","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"University of Ulm","has_results":false},{"nct_id":"NCT05748691","title":"Switching From Cardiac Troponin I to T","phase":"","overall_status":"COMPLETED","enrollment_count":26000,"lead_sponsor_name":"University of Edinburgh","has_results":false},{"nct_id":"NCT06707987","title":"Post-registration Trial of the Non-immunogenic Staphylokinase in Acute Ischemic Stroke (FORPI Registry)","phase":"","overall_status":"COMPLETED","enrollment_count":23250,"lead_sponsor_name":"Supergene, LLC","has_results":false},{"nct_id":"NCT06884436","title":"Preoperative Cardiology Consultation and the Incidence of Major Adverse Cardiac Events（MACE）","phase":"","overall_status":"COMPLETED","enrollment_count":22000,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT05247333","title":"Implementation of a Minor Ailment Service in Community Pharmacy Practice","phase":"NA","overall_status":"COMPLETED","enrollment_count":20987,"lead_sponsor_name":"Universidad de Granada","has_results":false},{"nct_id":"NCT06613074","title":"Ali Pay Intelligent Navigation Applet-aided Pre-hospital Triage for Non-emergency Medical Service Patients With Acute Ischemic Stroke","phase":"NA","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT06917612","title":"Preserving or Resecting the Normal Appendix in Patients Undergoing Laparoscopy Surgery for Suspected Appendicitis","phase":"","overall_status":"COMPLETED","enrollment_count":20000,"lead_sponsor_name":"Herlev Hospital","has_results":false},{"nct_id":"NCT07246213","title":"CAYA Cancer Retrospective Cohort Study","phase":"","overall_status":"RECRUITING","enrollment_count":18000,"lead_sponsor_name":"Resonance, Inc.","has_results":false},{"nct_id":"NCT01142427","title":"Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","phase":"","overall_status":"COMPLETED","enrollment_count":17463,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT03684629","title":"Computer Scan Based Analysing System on Improving Stroke Management Quality Evaluation","phase":"NA","overall_status":"UNKNOWN","enrollment_count":16570,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT03433521","title":"Observational Study of Spatio-Temporal Patterns of New Cases of Acute Myeloid Leukemia","phase":"","overall_status":"COMPLETED","enrollment_count":15000,"lead_sponsor_name":"Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz","has_results":false},{"nct_id":"NCT01994720","title":"[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":13307,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT05686070","title":"A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":12327,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT03354429","title":"THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":11016,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT06904664","title":"An Application That Can Provide Early Warning of Temperature Health Risks and Give Protective Suggestions or Personalized Suggestions Based on Patients' Own Secondary Prevention Risk Factors Was Applied to Intervene, and the Intervention Effect of APP on Stroke Recurrence Risk Was Analyzed","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":10184,"lead_sponsor_name":"Xuanwu Hospital, Beijing","has_results":false},{"nct_id":"NCT05154370","title":"China National Registry of Neuro-Inflammatory Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Beijing Tiantan Hospital","has_results":false},{"nct_id":"NCT06118281","title":"ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT04806620","title":"Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Brain Inflammation Collaborative","has_results":false},{"nct_id":"NCT07096973","title":"Cardiac REhabilitation COhort at the Medicine Campus DaVos to invEstigate Recovery","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Hochgebirgsklinik Davos","has_results":false},{"nct_id":"NCT05864638","title":"Acute Ischemic Stroke EndoVascular Therapy: a Multicenter REGISTRY Study","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Changhai Hospital","has_results":false},{"nct_id":"NCT07153744","title":"Efficacy and Safety of Shexiang Baoxin Pill(MUSKARDIA) in the Treatment of Acute Myocardial Infarction","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":9588,"lead_sponsor_name":"Shanghai Hutchison Pharmaceuticals Limited","has_results":false},{"nct_id":"NCT01190930","title":"Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":9350,"lead_sponsor_name":"Children's Oncology Group","has_results":true},{"nct_id":"NCT06125236","title":"Registration of Acute Ischemic Stroke With Large and Medium-sized Vascular Occlusion in Southwest China(LMVOS)","phase":"","overall_status":"RECRUITING","enrollment_count":8000,"lead_sponsor_name":"Zhengzhou Yuan","has_results":false},{"nct_id":"NCT03928119","title":"reGional Network for Acute Myocardial Infarction","phase":"NA","overall_status":"UNKNOWN","enrollment_count":7102,"lead_sponsor_name":"Guangdong Provincial People's Hospital","has_results":false},{"nct_id":"NCT06443333","title":"National, Multicentric Registry Study on Neuroimmunological Diseases in China","phase":"","overall_status":"RECRUITING","enrollment_count":7000,"lead_sponsor_name":"Xuanwu Hospital, Beijing","has_results":false},{"nct_id":"NCT05541224","title":"A Retrospective Epidemiologic Registry to Gain Insight Into the Characteristics and Prognosis of AML Patients According to the Routinely Used Genetic and Biologic Markers","phase":"","overall_status":"COMPLETED","enrollment_count":6917,"lead_sponsor_name":"PETHEMA Foundation","has_results":false},{"nct_id":"NCT03914625","title":"A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6720,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03635749","title":"Intensive Medical Therapy for High-risk Intracranial or Extracranial Atherosclerosis","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":6100,"lead_sponsor_name":"Beijing Tiantan Hospital","has_results":false},{"nct_id":"NCT07400601","title":"A Clinical Cohort Registry Study on Primary PCI for Acute Myocardial Infarction at Zhongshan Hospital","phase":"","overall_status":"RECRUITING","enrollment_count":6000,"lead_sponsor_name":"Shanghai Zhongshan Hospital","has_results":false},{"nct_id":"NCT05378490","title":"The Akershus Study of Ischemic Stroke and Thrombolysis -1","phase":"","overall_status":"RECRUITING","enrollment_count":6000,"lead_sponsor_name":"University Hospital, Akershus","has_results":false},{"nct_id":"NCT07471763","title":"Prospective Lifespan Cohort of Myocardial Infarction","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":6000,"lead_sponsor_name":"Fujian Provincial Hospital","has_results":false},{"nct_id":"NCT03959085","title":"Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":5951,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT02883049","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":5949,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT00103285","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":5377,"lead_sponsor_name":"Children's Oncology Group","has_results":true},{"nct_id":"NCT06853535","title":"Precision Antiplatelet Therapy Guided by Platelet Aggregation Function in Patients With Acute Ischemic STROKE","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":5138,"lead_sponsor_name":"Sichuan Provincial People's Hospital","has_results":false},{"nct_id":"NCT07097428","title":"An Application Provides Temperature-related Health Risk Warnings and Protective Recommendations on Stroke","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":5092,"lead_sponsor_name":"Xuanwu Hospital, Beijing","has_results":false},{"nct_id":"NCT07098143","title":"An Application Provides Personalized Suggestions Based on Secondary Prevention Risk Factors to Stroke Patients","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":5092,"lead_sponsor_name":"Xuanwu Hospital, Beijing","has_results":false},{"nct_id":"NCT06710184","title":"Treatment With Aspirin Alone Versus Aspirin in Combination With Fondaparinux Before Early Coronary Assessment in Patients With Non-ST-Elevation Myocardial Infarction","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":5076,"lead_sponsor_name":"University of Aarhus","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}